APROACH: Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)
Study Details
Study Description
Brief Summary
This proposal has three aims to characterize the relationship between aspirin therapy, platelet function response, and prevention of hypertensive disorders of pregnancy (HDP) through a prospective, cohort study using pharmacokinetics, pharmacodynamics, pharmacogenomics and bioinformatics. The results of this proposal will provide necessary data for prospective study on individualized aspirin dose adjustment for prevention of HDP.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This proposal has four aims to characterize the relationship between aspirin therapy, platelet function response, and prevention of HDP through a prospective, cohort study using pharmacodynamics, pharmacogenomics and bioinformatics. The results of this proposal will provide necessary data for prospective study on individualized aspirin dose adjustment for prevention of HDP.
Aim 1: Establish pharmacodynamic endpoints for aspirin in prevention of HDP Hypothesis:
PFA-100 closure time and serum thromboxane/urinary dehydrothromboxane-B2 (dTX-B2) are pharmacodynamic markers of aspirin response and are predictive of HDP high risk pregnant patients.
Aim 2: Explore aspirin pharmacogenetics by assessing the relationship between platelet receptor genotype, aspirin response, and prevention of HDP Hypothesis: Platelet receptor genotype is associated with race and may result in reduced platelet response to aspirin therapy, and increased incidence of HDP.
Aim 3: Assess the utility of circulating microRNA as a marker of aspirin response in pregnancy and risk of HDP Hypothesis: Quantitative expression of selected miRNAs are biomarkers for response to aspirin therapy and risk of HDP.
Aim 4: Evaluate aspirin pharmacokinetics/pharmacodynamics Hypothesis: Individual factors influence aspirin pharmacokinetics/pharmacodynamics and may impact individual dosing of aspirin
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Low Dose Aspirin Pregnant singletons at high risk for preeclampsia based on: at least one high risk factor for preeclampsia: prior preeclampsia, chronic hypertension, pregestational diabetes, lupus, antiphospholipid antibody syndrome, or chronic kidney disease. OR at least two of the following: BMI>30, black race, state insurance, IVF pregnancy, advanced maternal age, nulliparous or >10yr from last delivery, prior adverse pregnancy outcome who are planning to, but have not yet started, aspirin therapy <16 weeks' gestation. Patients will take 81mg aspirin as prescribed. |
Drug: Aspirin 81 mg
Aspirin 81mg daily PO
|
Outcome Measures
Primary Outcome Measures
- Aim 1: PFA-100 closure time and risk of hypertensive disorder of pregnancy (HDP) [8 months (delivery)]
Difference in first trimester PFA-100 closure time between patients started on aspirin who do and do not develop HDP
- Aim 2: Pharmacogenomics of aspirin [2 weeks]
Difference in PFA-100 closure time with aspirin therapy based on platelet receptor genotype
- Aim 3: MicroRNAs and HDP [8 months (delivery)]
Regression analysis to evaluate how miRNAs 223, 126, 155, 181a, 18a, 16 levels in first trimester are associated with risk of HDP
- Aim 4: Aspirin pharmacokinetics in pregnancy [2 weeks]
Define population based pharmacokinetic model of aspirin in first trimester of pregnancy taking into consideration individual factors (gestational age, race, BMI, genotype)
Secondary Outcome Measures
- Aim 1: Aspirin response [2 weeks]
Multiple logisitic regression analysis to evaluate factors (BMI, race, gestational age, genotype) associated with rate of nonresponse to aspirin therapy defined as (PFA-100>150s)
- Aim 1: Prediction of HDP [8 months (delivery)]
ROCC curve to determine threshold PFA-100 closure time after 1 week of aspirin therapy that is predictive of HDP
- Aim 1: First trimester serum thromboxane and risk of HDP [8 months (delivery)]
Comparison between first trimester serum thromboxane in those with and without hypertensive disorder of pregnancy
- Aim 1: Third trimester serum thromboxane and risk of HDP [8 months (delivery)]
Comparison between third trimester serum thromboxane in those with and without hypertensive disorder of pregnancy
- Aim 2: Pharmacogenomics and Pregnancy outcome [8 months (delivery)]
Multiple regression analysis taking into consideration platelet receptor genotype, race, BMI, and other clinical characteristics and prediction of HDP
- Aim 3: MicroRNA profile and aspirin therapy [2 weeks]
Paired comparison to evaluate how miRNAs 223, 126, 155, 181a, 18a, 16 levels change before and after aspirin therapy
- Aim 4: Salicylic acid level and Serum Thromboxane [2 weeks]
Association between serum salicylic acid with aspirin therapy and serum thromboxane with aspirin therapy
- Predictors of preterm birth [8 months (delivery)]
Multivariable logistic regression to evaluate markers predictive of preterm birth
- Predictors of preeclampsia [8 months (delivery)]
Multivariable logistic regression to evaluate markers predictive of preeclampsia and preterm preeclampsia
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Pregnant singleton, <16 weeks' gestation
-
At least one high risk factor for preeclampsia: prior preeclampsia, chronic hypertension, pregestational diabetes, chronic kidney disease, lupus, antiphospholipid antibody syndrome
Exclusion Criteria:
-
Contraindication to aspirin
-
Current or planned use of any other anticoagulation
-
Use of aspirin in pregnancy prior to enrollment
-
Known platelet disorder at time of enrollment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | United States | 19107 |
Sponsors and Collaborators
- Thomas Jefferson University
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- March of Dimes
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 19F.887
- R21HD101127